(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-0.15%) $77.99
(0.37%) $2.15
(0.06%) $2 310.10
(0.36%) $26.79
(0.09%) $966.20
(-0.36%) $0.929
(-0.97%) $10.89
(-0.15%) $0.797
(0.52%) $91.61
2 days till quarter result
(amc 2024-05-07)
Expected move: +/- 6.00%
Live Chart Being Loaded With Signals
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally...
Stats | |
---|---|
今日成交量 | 9 703.00 |
平均成交量 | 10 070.00 |
市值 | 22.40M |
EPS | $0 ( 2024-03-05 ) |
下一个收益日期 | ( $0 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.59 |
ATR14 | $0.0100 (0.62%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-25 | Krogulski Kenneth | Buy | 5 000 | Common Stock |
2024-03-25 | Jones James | Buy | 1 000 | Common Stock |
2024-03-25 | Galante Joseph C | Buy | 1 000 | Common Stock |
2024-03-25 | Young Caroline | Buy | 1 000 | Common Stock |
2024-03-25 | Brown Martin S Jr | Buy | 1 000 | Common Stock |
INSIDER POWER |
---|
64.38 |
Last 100 transactions |
Buy: 135 322 | Sell: 29 102 |
Cumberland 财务报表
Annual | 2023 |
营收: | $39.55M |
毛利润: | $28.55M (72.18 %) |
EPS: | $-0.440 |
FY | 2023 |
营收: | $39.55M |
毛利润: | $28.55M (72.18 %) |
EPS: | $-0.440 |
FY | 2022 |
营收: | $42.01M |
毛利润: | $32.89M (78.29 %) |
EPS: | $-0.390 |
FY | 2021 |
营收: | $35.99M |
毛利润: | $27.17M (75.51 %) |
EPS: | $-0.240 |
Financial Reports:
No articles found.
Cumberland
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。